SC-558 | CAS#unknown | COX-2 selective inhibitor

MedKoo Cat#: 464535 | Name: SC-558

Description:

WARNING: This product is for research use only, not for human or veterinary use.

SC-558 is a COX-2 selective inhibitor with COX-2 IC50 = 9.3 nM.

Chemical Structure

SC-558

CAS#unknown

Theoretical Analysis

MedKoo Cat#: 464535

Name: SC-558

CAS#: unknown

Chemical Formula: C16H11BrF3N3O2S

Exact Mass: 444.9707

Molecular Weight: 446.24

Elemental Analysis: C, 43.07; H, 2.48; Br, 17.91; F, 12.77; N, 9.42; O, 7.17; S, 7.18

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

SC-558; SC558; SC 558;

IUPAC/Chemical Name

4-(5-(4-bromophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide

InChi Key

OYZKFVIVPRQRQQ-UHFFFAOYSA-N

InChi Code

InChI=1S/C16H11BrF3N3O2S/c17-11-3-1-10(2-4-11)14-9-15(16(18,19)20)22-23(14)12-5-7-13(8-6-12)26(21,24)25/h1-9H,(H2,21,24,25)

SMILES Code

O=S(C1=CC=C(N2C(C3=CC=C(Br)C=C3)=CC(C(F)(F)F)=N2)C=C1)(N)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 446.24 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Hassan GS, Abdel Rahman DE, Abdelmajeed EA, Refaey RH, Alaraby Salem M, Nissan YM. New pyrazole derivatives: Synthesis, anti-inflammatory activity, cycloxygenase inhibition assay and evaluation of mPGES. Eur J Med Chem. 2019 Jun 1;171:332-342. doi: 10.1016/j.ejmech.2019.03.052. Epub 2019 Mar 23. PMID: 30928706. 2: Murahari M, Mahajan V, Neeladri S, Kumar MS, Mayur YC. Ligand based design and synthesis of pyrazole based derivatives as selective COX-2 inhibitors. Bioorg Chem. 2019 May;86:583-597. doi: 10.1016/j.bioorg.2019.02.031. Epub 2019 Feb 14. PMID: 30782576. 3: Farzaneh S, Shahhosseini S, Arefi H, Daraei B, Esfahanizadeh M, Zarghi A. Design, Synthesis and Biological Evaluation of New 1,3-diphenyl-3- (phenylamino)propan-1-ones as Selective Cyclooxygenase (COX-2) Inhibitors. Med Chem. 2018;14(7):652-659. doi: 10.2174/1573406414666180525133221. PMID: 29804536. 4: Hadianawala M, Mahapatra AD, Yadav JK, Datta B. Molecular docking, molecular modeling, and molecular dynamics studies of azaisoflavone as dual COX-2 inhibitors and TP receptor antagonists. J Mol Model. 2018 Feb 26;24(3):69. doi: 10.1007/s00894-018-3620-0. PMID: 29480373. 5: Madhava G, Ramana KV, Sudhana SM, Rao DS, Kumar KH, Lokanatha V, Rani AU, Raju CN. Aryl/heteroaryl Substituted Celecoxib Derivatives as COX-2 Inhibitors: Synthesis, Anti-inflammatory Activity and Molecular Docking Studies. Med Chem. 2017;13(5):484-497. doi: 10.2174/1573406413666170221093740. PMID: 28228088. 6: Abdel-Sayed MA, Bayomi SM, El-Sherbeny MA, Abdel-Aziz NI, ElTahir KE, Shehatou GS, Abdel-Aziz AA. Synthesis, anti-inflammatory, analgesic, COX-1/2 inhibition activities and molecular docking study of pyrazoline derivatives. Bioorg Med Chem. 2016 May 1;24(9):2032-42. doi: 10.1016/j.bmc.2016.03.032. Epub 2016 Mar 18. PMID: 27025563. 7: Alanazi AM, El-Azab AS, Al-Suwaidan IA, ElTahir KE, Asiri YA, Abdel-Aziz NI, Abdel-Aziz AA. Structure-based design of phthalimide derivatives as potential cyclooxygenase-2 (COX-2) inhibitors: anti-inflammatory and analgesic activities. Eur J Med Chem. 2015 Mar 6;92:115-23. doi: 10.1016/j.ejmech.2014.12.039. Epub 2014 Dec 24. PMID: 25549551. 8: Limongelli V, Bonomi M, Parrinello M. Funnel metadynamics as accurate binding free-energy method. Proc Natl Acad Sci U S A. 2013 Apr 16;110(16):6358-63. doi: 10.1073/pnas.1303186110. Epub 2013 Apr 3. PMID: 23553839; PMCID: PMC3631651. 9: Al-Suwaidan IA, Alanazi AM, El-Azab AS, Al-Obaid AM, ElTahir KE, Maarouf AR, Abu El-Enin MA, Abdel-Aziz AA. Molecular design, synthesis and biological evaluation of cyclic imides bearing benzenesulfonamide fragment as potential COX-2 inhibitors. Part 2. Bioorg Med Chem Lett. 2013 May 1;23(9):2601-5. doi: 10.1016/j.bmcl.2013.02.107. Epub 2013 Mar 7. PMID: 23528298. 10: Estevão MS, Carvalho LC, Freitas M, Gomes A, Viegas A, Manso J, Erhardt S, Fernandes E, Cabrita EJ, Marques MM. Indole based cyclooxygenase inhibitors: synthesis, biological evaluation, docking and NMR screening. Eur J Med Chem. 2012 Aug;54:823-33. doi: 10.1016/j.ejmech.2012.06.040. Epub 2012 Jun 29. PMID: 22796043. 11: El-Sayed MA, Abdel-Aziz NI, Abdel-Aziz AA, El-Azab AS, ElTahir KE. Synthesis, biological evaluation and molecular modeling study of pyrazole and pyrazoline derivatives as selective COX-2 inhibitors and anti-inflammatory agents. Part 2. Bioorg Med Chem. 2012 May 15;20(10):3306-16. doi: 10.1016/j.bmc.2012.03.044. Epub 2012 Mar 29. PMID: 22516672. 12: Hayun, Yanuar A, Hanafi M, Pws SH. Virtual screening of 2,3-disubstituted-4(3H)-quinazolinones possessing benzenesulfonamide moiety for COX-2 inhibitor. Bioinformation. 2011;7(5):246-50. doi: 10.6026/97320630007246. Epub 2011 Oct 31. PMID: 22125393; PMCID: PMC3218419. 13: El-Sayed MA, Abdel-Aziz NI, Abdel-Aziz AA, El-Azab AS, Asiri YA, Eltahir KE. Design, synthesis, and biological evaluation of substituted hydrazone and pyrazole derivatives as selective COX-2 inhibitors: Molecular docking study. Bioorg Med Chem. 2011 Jun 1;19(11):3416-24. doi: 10.1016/j.bmc.2011.04.027. Epub 2011 Apr 22. PMID: 21570309. 14: Abdel-Aziz AA, ElTahir KE, Asiri YA. Synthesis, anti-inflammatory activity and COX-1/COX-2 inhibition of novel substituted cyclic imides. Part 1: Molecular docking study. Eur J Med Chem. 2011 May;46(5):1648-55. doi: 10.1016/j.ejmech.2011.02.013. Epub 2011 Feb 15. PMID: 21388719. 15: Jiang B, Zeng Y, Li MJ, Xu JY, Zhang YN, Wang QJ, Sun NY, Lu T, Wu XM. Design, synthesis, and biological evaluation of 1,5-diaryl-1,2,4-triazole derivatives as selective cyclooxygenase-2 inhibitors. Arch Pharm (Weinheim). 2010 Sep;343(9):500-8. doi: 10.1002/ardp.200900227. PMID: 20842641. 16: Bouaziz-Terrachet S, Toumi-Maouche A, Maouche B, Taïri-Kellou S. Modeling the binding modes of stilbene analogs to cyclooxygenase-2: a molecular docking study. J Mol Model. 2010 Dec;16(12):1919-29. doi: 10.1007/s00894-010-0679-7. Epub 2010 Mar 17. PMID: 20237816. 17: Limongelli V, Bonomi M, Marinelli L, Gervasio FL, Cavalli A, Novellino E, Parrinello M. Molecular basis of cyclooxygenase enzymes (COXs) selective inhibition. Proc Natl Acad Sci U S A. 2010 Mar 23;107(12):5411-6. doi: 10.1073/pnas.0913377107. Epub 2010 Mar 9. PMID: 20215464; PMCID: PMC2851773. 18: El-Gamal MI, Bayomi SM, El-Ashry SM, Said SA, Abdel-Aziz AA, Abdel-Aziz NI. Synthesis and anti-inflammatory activity of novel (substituted)benzylidene acetone oxime ether derivatives: molecular modeling study. Eur J Med Chem. 2010 Apr;45(4):1403-14. doi: 10.1016/j.ejmech.2009.12.041. Epub 2009 Dec 28. PMID: 20079558. 19: Hyde CA, Missailidis S. Inhibition of arachidonic acid metabolism and its implication on cell proliferation and tumour-angiogenesis. Int Immunopharmacol. 2009 Jun;9(6):701-15. doi: 10.1016/j.intimp.2009.02.003. Epub 2009 Feb 23. PMID: 19239926. 20: Sudha KN, Shakira M, Prasanthi P, Sarika N, Kumar ChN, Babu PA. Virtual screening for novel COX-2 inhibitors using the ZINC database. Bioinformation. 2008 May 13;2(8):325-9. doi: 10.6026/97320630002325. PMID: 18685718; PMCID: PMC2478730.